Podcast Episodes
Back to SearchNew Data on Risk Factors and Treatment Regimens for Patients With Neovascular AMD and DME
Episode 616
Drs. Vakharia and Danzig highlight new AAO 2025 data on high-dose aflibercept, sleep apnea as a potential AMD risk factor, and an AI-guided anti-VEGF…
5 months, 2 weeks ago
Can oral semaglutide reduce heart failure events in patients with heart failure with preserved ejection fraction?
Episode 615
Oral semaglutide reduced heart failure hospitalizations and cardiovascular death in type 2 diabetes patients with existing heart failure, particularl…
5 months, 2 weeks ago
2025 San Antonio Breast Cancer Symposium: Key Updates in Early-Stage HER2+ Breast Cancer
Episode 614
Drs. Isaacs and Traina discuss new data in HER2+ breast cancer from the 2025 San Antonio Breast Cancer Symposium, focusing on early-stage studies inc…
5 months, 2 weeks ago
CLL at ASH 2025: BRUIN Studies and a Triplet for Richter Transformation
Episode 613
Drs. Wierda and O’Brien discuss emerging data showing the non-covalent BTK inhibitor pirtobrutinib outperforming traditional chemoimmunotherapy and s…
5 months, 2 weeks ago
Could new pulmonary embolism guidelines safely reduce hospitalizations for some patients?
Episode 612
New AHA/ACC guidelines overhaul pulmonary embolism management with a five-tier risk classification, endorsing ED discharge for low-risk patients and …
5 months, 3 weeks ago
Evolving HER2+ Testing and Targeted Therapies in GI Cancers: Latest Insights From ESMO 2025
Episode 611
Drs. Cytryn, Foote, and Thummalapalli discuss recent data on HER2 testing modalities and the prevalence of HER2 positivity across hepatobiliary, uppe…
5 months, 3 weeks ago
OnabotulinumtoxinA and Migraine: Clinical Insights and Recent Evidence
Episode 610
Drs. Ailani and Dougherty discuss onabotulinumtoxinA, a cornerstone treatment for chronic migraine, which reduces headache days and disability when g…
5 months, 3 weeks ago
Can achieving prediabetes remission cut CV death and heart failure risk?
Episode 609
Three major studies reshape preventive care. Long-term follow-up from diabetes prevention trials, published in The Lancet Diabetes & Endocrinology, s…
6 months ago
HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025
Episode 608
Drs. Dizon and Campos discuss how new antibody drug conjugates like trastuzumab deruxtecan are transforming treatment options for HER2+ gynecological…
6 months ago
HER2+ Endometrial and Ovarian Cancers: Targeted Therapy Highlights From ESMO 2025
Episode 608
Drs. Dizon and Campos discuss how new antibody drug conjugates like trastuzumab deruxtecan are transforming treatment options for HER2+ gynecological…
6 months ago